Sales & Marketing News | pharmaphorum

News

Hikma will pay $150m in US opioid settlement

Indian drugmaker Hikma has agreed in principle to a $150 million settlement to resolve lawsuits claiming that it contributed to the opioid crisis in the US, which could al

News

FDA sets date for Adaptimmune’s sarcoma drug verdict

The FDA is due to decide by 4th August whether to approve Adaptimmune’s engineered T-cell therapy for advanced synovial sarcoma, afamitresgene autoleucel (afami-cel), afte

News

GSK on top in RSV jab rollout, but is Pfizer closing the gap...

GSK and Pfizer’s full-year financial results show that the former is currently winning the battle for take-up of their rival respiratory syncytial virus (RSV) vaccines, al

News

Novo Nordisk sales surge drives value towards $500bn

Fuelled by its diabetes and obesity drugs, Novo Nordisk has reported revenues up a third in 2023, sparking a rise in an already inflated share price that briefly pushed th

News

US bill paints some Chinese biotechs as security threats

Legislation tabled in the US is seeking to block Chinese life sciences companies from claiming federal funding and contracts on the grounds they are a national security co

News

FDA starts swift review of tumour-agnostic use of Enhertu

AstraZeneca and Daiichi Sankyo’s Enhertu could become the first therapy approved by the FDA for use in any HER2-positive cancer, regardless of its location in the body.

Hikma will pay $150m in US opioid settlement

FDA sets date for Adaptimmune’s sarcoma drug verdict

GSK on top in RSV jab rollout, but is Pfizer closing the gap...

Novo Nordisk sales surge drives value towards $500bn

US bill paints some Chinese biotechs as security threats

FDA starts swift review of tumour-agnostic use of Enhertu

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks